Want to see NEPH full AI Analyst Report?
Nephros (NEPH) Stock Price & Analysis
NEPH Stock Chart & Stats
- Day’s Range
- $2.72 - $3.08
- 52-Week Range
- $2.66 - $6.42
- Previous Close
- $3.09
- Volume
- N/A
- Average Volume (3M)
- 52.34K
- Market Cap
- $30.33M
- Enterprise Value
- $37.79M
- Total Cash (Recent Filing)
- $4.55M
- Total Debt (Recent Filing)
- $774.00K
- Price to Earnings (P/E)
- 15.6
- Beta
- -0.06
- Next Earnings
- Mar 11, 2027 (Est.)
- EPS Estimate
- 0.01
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Recurring Customer Base
A record active customer base with reorder activity supports recurring replacement-filter demand and improves revenue visibility. Continued site additions can compound this installed-base effect, while deeper customer relationships may create opportunities for service and broader water-management offerings.
Revenue And Earnings Growth
Double-digit revenue growth alongside higher net income indicates that Nephros is expanding demand while converting more sales into earnings. If sustained, this combination can strengthen internal funding capacity, support commercial investment, and improve the company’s competitive position.
Conservative Balance Sheet
A debt-free balance sheet and meaningful cash balance provide financial flexibility as Nephros expands products, services, education, and market coverage. Low financial leverage reduces fixed financing obligations and leaves more capacity to fund growth initiatives or absorb operating variability.
Bears Say
Weak Cash Conversion
Negative operating and free cash flow despite positive earnings signals that reported profitability is not currently translating into cash generation. Persistent weak conversion could increase reliance on working-capital movements or existing liquidity and constrain the pace of internally funded expansion.
Margin And Cost Pressure
Lower gross margin and faster cost-of-goods growth can limit operating leverage even while revenue expands. Tariffs, shipping, handling, and the increasing mix of lower-margin service and commercial revenue may keep profitability under pressure unless pricing, scale, or product mix improves.
Slow And Uneven Commercial Adoption
Long enterprise sales cycles delay conversion of commercial opportunities into revenue and make growth investments slower to pay back. The separate volatility of emergency-response activity adds unpredictability, leaving the durable growth strategy dependent on steadier programmatic and service adoption.
NEPH FAQ
What was Nephros’s price range in the past 12 months?
What is Nephros’s market cap?
When is Nephros’s upcoming earnings report date?
How were Nephros’s earnings last quarter?
Is Nephros overvalued?
Does Nephros pay dividends?
What is Nephros’s EPS estimate?
How many shares outstanding does Nephros have?
What happened to Nephros’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Nephros?
What is the TipRanks Smart Score and how is it calculated?
Nephros Stock Smart Score
Company Description
Nephros
Nephros, Inc. is a company that specializes in developing and marketing sophisticated water purification solutions across the United States, catering to both the medical and commercial sectors. Its operations are structured into three primary segments: Water Filtration, Pathogen Detection, and Renal Products. Within its Water Filtration division, Nephros offers advanced ultrafiltration products. These are vital in dialysis centers for eradicating biological contaminants from water and bicarbonate concentrate, and are also deployed in hospitals to prevent infections from waterborne pathogens such as Legionella and Pseudomonas. Their utility extends to military installations, outdoor recreation, commercial establishments, and various other healthcare facilities. The Pathogen Detection segment focuses on developing and distributing real-time water testing systems, which deliver critical, actionable data regarding waterborne pathogens. Furthermore, under its Renal Products segment, the company provides medical devices designed for individuals suffering from renal disease, notably including a second-generation hemodiafiltration system tailored for patients with end-stage renal disease. Additionally, Nephros markets a range of water filters under the Nephros and AETHER brands. These filters are engineered not only to enhance water taste and eliminate odors but also to significantly reduce biofilm, bacteria, and scale accumulation in downstream equipment, serving the food service, hospitality, convenience store, and healthcare industries. Established in 1997, Nephros, Inc. maintains its corporate headquarters in South Orange, New Jersey.
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- CEO
- Robert Banks
- Employees
- 36
- Website
- www.nephros.com
- Address
- 380 Lackawanna Place, South Orange, NJ, 07079, US
Nephros (NEPH) Earnings & Revenues
NEPH Earnings Call
Earnings Call SentimentPositive
The call was strongly positive overall. Nephros reported double-digit revenue growth, higher net income and adjusted EBITDA, a record active customer base, continued programmatic and service expansion, broader market applications, and a debt-free balance sheet. These strengths were partly offset by lower gross margins, higher product and operating costs, volatility in emergency response revenue, long commercial sales cycles, and still-developing education ROI metrics.
View all NEPH earnings summariesNEPH Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 2 | 14 |
| Technical Analysis | 6 | 2 | 2 |
| Moving Averages | 0 | 0 | 12 |
